Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epicensus

- PMLiVE

Almirall launches mini-series to highlight impact of psoriasis on patient well-being

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Eli Lilly to acquire Dice Therapeutics for approximately $2.4bn

The deal marks a significant expansion to Lilly's immunology pipeline

EU flag

European Commission grants two new marketing authorisations for UCB’s Bimzelx

The drug is now approved to treat psoriatic arthritis and axial spondyloarthritis

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

- PMLiVE

Amgen reports positive results for inflammatory disease drug Otezla in psoriatic arthritis

The inflammatory condition is estimated to affect nearly 38 million people worldwide

- PMLiVE

Almirall and CRG announce non-melanoma skin cancer research collaboration

The partners will jointly develop novel preclinical models to identify new treatments for NMSC

- PMLiVE

Putting Skin in the Game at AAD 2023

AAD has wrapped up in New Orleans, and the Medscape team have returned home from another successful conference.During the conference, Medscape hosted one educational symposium, Reframing the Management Approach for...

Medscape Education Global

- PMLiVE

UCB’s bimekizumab shows continued improvement in hidradenitis suppurativa patients

There is currently only one approved biologic treatment for the inflammatory skin disease

- PMLiVE

LEO Pharma enters clinical trial partnership with ICON

The collaboration will focus on advancing clinical trial execution within medical dermatology

EU flag

EC approves UCB’s Fintepla to treat severe form of epilepsy

Lennox-Gastaut syndrome affects around two in 10,000 people in the EU and usually begins in early childhood

- PMLiVE

Boehringer’s Spevigo receives EC approval for generalised pustular psoriasis flares

Trial showed 54% of patients were free of pustules one week after a single dose

- PMLiVE

UCB’s Epicensus programme highlights need to address psoriasis care gap

The programme was published in Dermatology and Therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links